FYI: This is a press release for your information. This is not an endorsement for, against or otherwise.
Cannformatics Announces Publication of Groundbreaking Study Identifying Cannabis-Responsive™ Biomarkers in Children with Autism Spectrum Disorder
First study to examine the metabolic response in saliva of children with ASD treated with various medical cannabis/CBD products widely available in licensed California dispensaries.
SAN FRANCISCO, Dec. 8, 2021 /PRNewswire/ —
- Study results indicate the potential of Cannabis-Responsive biomarkers as a powerful tool in quantifying, at the metabolic level, the benefits of successful medical cannabis treatment in children with ASD.
- Study results also show the potential of Cannabis-Responsive biomarkers to provide insights into the mechanism of action of medical cannabis treatment, a first step toward improving medical cannabis treatment for people with ASD of all ages as well as other neurological disorders.
- The paper “Cannabis-Responsive Biomarkers: a pharmacometabolomics-based application to evaluate the impact of medical cannabis treatment on children with ASD” is published and available to read in the journal Cannabis and Cannabinoid Research and at Cannformatics.com/asd-study.
Cannformatics, an early-stage biotechnology startup focused on personalizing medical cannabis treatment through the identification and application of saliva-based Cannabis-Responsive biomarkers, announced today that the journal Cannabis and Cannabinoid Research has published results from its observational pilot study of children with ASD. Participants in the study were racially, ethnically, and socio-economically diverse boys and girls ages 6-12 years old whose symptoms span the autism spectrum. The study successfully identifies a new class of metabolites, Cannabis-Responsive biomarkers, that objectively quantify the physiological impact of medical cannabis treatment and provide a tool for investigating the metabolic pathways affected by medical cannabis and CBD. The underlying technology and study methodology were developed by a multi-disciplinary team of experts in biochemistry, bioinformatics, data science, neuropsychology, pediatrics, integrative oncology, emergency medicine, and the medical cannabis industry.
“One of our primary goals was to scientifically validate Cannabis-Responsive biomarkers as a universal measurement for evaluating cannabis impact. The publishing of this paper achieves that goal, and it represents over three-years of research developing a biomarker technology for objectively determining the impact of commercially available medical cannabis products,” said Itzhak Kurek, PhD, Cannformatics CEO and Cofounder. “Based on the strong findings from this study, we are expanding our platform development to include chronic neuropathic pain, anxiety, and chemotherapy-induced nausea and vomiting. We are forever grateful to all the participating children and their families who made this work possible.”
“The lack of objective data contributes to the confusion and stigma patients face when looking to medical cannabis to improve wellness and quality-of-life. Cannabis-Responsive biomarkers give the industry a new set of tools to quantitatively evaluate the medical impact of legally available cannabis and CBD products,” said Chief Commercial Officer and Cofounder, Kenneth Epstein. “We felt it was important to publish and publicly share our findings as a demonstration of our commitment to both the ASD and medical cannabis communities. We want to thank our sponsors Canniatric and Whole Plant Access for Autism (WPA4A.org) for their generous support of the ASD Pilot Study.”
Donald Abrams, MD, study co-author, Cannformatics Science Advisor and UCSF School of Medicine Professor Emeritus, commented, “This study demonstrates that saliva-based Cannabis-Responsive biomarkers may be a valid tool for clinicians and researchers to use in evaluating the impact of medical cannabis. This opens up new avenues of medical cannabis research that will undoubtedly help patients and their doctors to have more informed conversations about the potential role of medical cannabis in managing symptoms.”
“As a medical cannabis clinician and pediatrician who treats many patients with autism, this study is very exciting because it shows for the first time that the positive outcomes I’m seeing from medical cannabis can be confirmed and quantified with Cannabis-Responsive biomarkers. The changes seen in these biomarker levels in response to medical cannabis treatment will help guide clinicians and parents to optimize treatment in children with autism,” said Bonni Goldstein, MD, study co-author and Cannformatics Clinical Advisor.
Cannformatics is an early-stage biotechnology startup focused on the development of Cannabis-Responsive™biomarkers found in saliva for personalized medical cannabis treatment, product development and other applications. The company’s mission is to develop technologies that enable predictable and repeatable science-based medical cannabis treatment to improve health and quality of life. The company is currently initiating a study of medical cannabis treatment for chronic neuropathic pain. Patient groups interested in participating in the study may email firstname.lastname@example.org for more information. Cannformatics is headquartered in San Francisco, CA. Follow us on Twitter @cannformatics.
Autistic people have fought the inclusion of ABA in therapy for us since before Autism Speaks, and other non-Autistic-led autism organizations, started lobbying legislation to get it covered by insurances and Medicaid.
ABA is a myth originally sold to parents that it would keep their Autistic child out of an institution. Today, parents are told that with early intervention therapy their child will either be less Autistic or no longer Autistic by elementary school, and can be mainstreamed in typical education classes. ABA is very expensive to pay out of pocket. Essentially, Autism Speaks has justified the big price tag up front will offset the overall burden on resources for an Autistic’s lifetime. The recommendation for this therapy is 40 hours a week for children and toddlers.
The original study that showed the success rate of ABA to be at 50% has never been replicated. In fact, the study of ABA by United States Department of Defense was denounced as a failure. Not just once, but multiple times. Simply stated: ABA doesn’t work. In study after repeated study: ABA (conversion therapy) doesn’t work.
What more recent studies do show: Autistics who experienced ABA therapy are at high risk to develop PTSD and other lifelong trauma-related conditions. Historically, the autism organizations promoting ABA as a cure or solution have silenced Autistic advocates’ opposition. ABA is also known as gay conversion therapy.
The ‘cure’ for Autistics not born yet is the prevention of birth.
The ‘cure’ is a choice to terminate a pregnancy based on ‘autism risk.’ The cure is abortion. This is the same ‘cure’ society has for Down Syndrome.
This is eugenics 2021. Instead of killing Autistics and disabled children in gas chambers or ‘mercy killings’ like in Aktion T4, it’ll happen at the doctor’s office, quietly, one Autistic baby at a time. Different approaches yes, but still eugenics and the extinction of an entire minority group of people.
Fact: You can’t cure Autistics from being Autistic.
Fact: You can’t recover an Autistic from being Autistic.
Fact: You can groom an Autistic to mask and hide their traits. Somewhat. … however, this comes at the expense of the Autistic child, promotes Autistic Burnout (this should not be confused with typical burnout, Autistic Burnout can kill Autistics), and places the Autistic child at high risk for PTSD and other lifelong trauma-related conditions.
[Note: Autism is NOT a disease, but a neurodevelopmental difference and disability.]
Fact: Vaccines Do Not Cause Autism.